| Assessment Status | Assessment process complete |
| HTA ID | – |
| Drug | Ixazomib |
| Brand | Ninlaro® |
| Indication | In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
| Assessment Process | |
| Rapid Review Commissioned | 23/11/2016 |
| Rapid review completed | 16/01/2017 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 23/01/2017 |
| Pre-submission consultation with Applicant | 06/02/2017 |
| Full submission received from Applicant | 01/06/2017 |
| Preliminary review sent to Applicant | 04/08/2017 |
| NCPE assessment re-commenced | 31/08/2017 |
| Factual accuracy sent to applicant | 20/11/2017 |
| NCPE assessment re-commenced | 04/12/2017 |
| Applicant factual accuracy check | 07/12/2017 |
| NCPE assessment re-commenced | 12/12/2017 |
| NCPE assesment completed | 18/12/2017 |
| NCPE assessment outcome | Reimbursement not recommended. |
The HSE has approved reimbursement following confidential price negotiations – December 2018.
